CY1120095T1 - Αναστολεις της erk και μεθοδοι χρησης - Google Patents
Αναστολεις της erk και μεθοδοι χρησηςInfo
- Publication number
- CY1120095T1 CY1120095T1 CY20181100340T CY181100340T CY1120095T1 CY 1120095 T1 CY1120095 T1 CY 1120095T1 CY 20181100340 T CY20181100340 T CY 20181100340T CY 181100340 T CY181100340 T CY 181100340T CY 1120095 T1 CY1120095 T1 CY 1120095T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- erk
- suspensions
- compositions
- compounds
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886552P | 2013-10-03 | 2013-10-03 | |
| US201462032446P | 2014-08-01 | 2014-08-01 | |
| PCT/US2014/059197 WO2015051341A1 (en) | 2013-10-03 | 2014-10-03 | Inhibitors of erk and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120095T1 true CY1120095T1 (el) | 2018-12-12 |
Family
ID=52779215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100340T CY1120095T1 (el) | 2013-10-03 | 2018-03-27 | Αναστολεις της erk και μεθοδοι χρησης |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US9624228B2 (https=) |
| EP (2) | EP3363800A1 (https=) |
| JP (2) | JP6427197B2 (https=) |
| KR (1) | KR20160081908A (https=) |
| CN (2) | CN105636586B (https=) |
| AU (2) | AU2014331628B2 (https=) |
| BR (1) | BR112016006994A8 (https=) |
| CA (1) | CA2924584A1 (https=) |
| CY (1) | CY1120095T1 (https=) |
| DK (1) | DK3052096T3 (https=) |
| EA (1) | EA032196B1 (https=) |
| ES (1) | ES2664794T3 (https=) |
| HK (1) | HK1255851A1 (https=) |
| HR (1) | HRP20180538T1 (https=) |
| HU (1) | HUE036600T2 (https=) |
| IL (1) | IL244488A0 (https=) |
| LT (1) | LT3052096T (https=) |
| ME (1) | ME02991B (https=) |
| MX (1) | MX2016004163A (https=) |
| PH (1) | PH12016500432A1 (https=) |
| PL (1) | PL3052096T3 (https=) |
| PT (1) | PT3052096T (https=) |
| RS (1) | RS57058B1 (https=) |
| SG (1) | SG11201602572YA (https=) |
| SI (1) | SI3052096T1 (https=) |
| SM (1) | SMT201800205T1 (https=) |
| WO (1) | WO2015051341A1 (https=) |
| ZA (1) | ZA201601701B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3363800A1 (en) | 2013-10-03 | 2018-08-22 | Kura Oncology, Inc. | Heterocyclic inhibitors of erk and methods of use |
| TW201805000A (zh) * | 2016-06-20 | 2018-02-16 | 庫拉腫瘤技術股份有限公司 | 利用erk抑制劑之鱗狀細胞癌之治療 |
| CN110506038B (zh) | 2017-03-28 | 2023-11-24 | 巴斯夫欧洲公司 | 杀害虫化合物 |
| WO2018183762A1 (en) | 2017-03-29 | 2018-10-04 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating cancer |
| US20200247815A1 (en) * | 2017-10-19 | 2020-08-06 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Pyrazolyl-containing tricyclic derivative, preparation method therefor and use thereof |
| CN109761986B (zh) * | 2017-11-10 | 2021-10-08 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
| CN107879989B (zh) * | 2017-11-29 | 2020-01-03 | 重庆市中药研究院 | 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法 |
| EP3643705A1 (en) | 2018-10-24 | 2020-04-29 | Basf Se | Pesticidal compounds |
| MX2021005171A (es) | 2018-11-16 | 2021-10-01 | California Inst Of Techn | Inhibidores de cinasas reguladas por señal extracelular (erk) y usos de los mismos. |
| CN112020357B (zh) * | 2019-04-02 | 2023-08-29 | 上海翰森生物医药科技有限公司 | 含吲唑基的三并环类衍生物的盐及其晶型 |
| EP3766879A1 (en) | 2019-07-19 | 2021-01-20 | Basf Se | Pesticidal pyrazole derivatives |
| WO2022075445A1 (ja) * | 2020-10-08 | 2022-04-14 | 株式会社Adeka | ポリオレフィン系樹脂組成物、それを用いた成形品、及びポリオレフィン系樹脂組成物の製造方法 |
| EP4198023A1 (en) | 2021-12-16 | 2023-06-21 | Basf Se | Pesticidally active thiosemicarbazone compounds |
| US20250197358A1 (en) | 2022-02-17 | 2025-06-19 | Basf Se | Pesticidally active thiosemicarbazone compounds |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2024240859A1 (en) | 2023-05-25 | 2024-11-28 | Basf Se | Lactam pesticidal compounds |
| EP4467535A1 (en) | 2023-05-25 | 2024-11-27 | Basf Se | Lactam pesticidal compounds |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| TW202529768A (zh) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | 癌症治療的療法 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| BE791816R (fr) | 1971-11-24 | 1973-05-23 | Sandoz Sa | Derives de la quinazolinone, leur preparation et medicaments contenant ces |
| US3984556A (en) * | 1973-01-19 | 1976-10-05 | Sandoz, Inc. | Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure |
| US4042704A (en) | 1976-03-18 | 1977-08-16 | Sandoz, Inc. | Benzindazoles |
| US4352931A (en) | 1980-05-22 | 1982-10-05 | Siegfried Aktiengesellschaft | Lin-benzoaminopurinols |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| DE3701277A1 (de) * | 1987-01-17 | 1988-07-28 | Boehringer Mannheim Gmbh | Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| DK0821671T3 (da) | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
| DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Agouron Pharmaceuticals, Inc. | Matrix-metalloprotease Inhibitoren |
| EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| WO1998007697A1 (en) | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| EP0977733B1 (en) | 1997-02-03 | 2003-09-03 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| EA002546B1 (ru) | 1997-02-11 | 2002-06-27 | Пфайзер Инк. | Производные арилсульфонилгидроксамовой кислоты |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| US6087368A (en) | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
| US6562836B1 (en) * | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP3896309B2 (ja) * | 2001-07-09 | 2007-03-22 | ファイザー株式会社 | プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体 |
| US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
| AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| US20050203063A1 (en) * | 2003-09-12 | 2005-09-15 | Raymond Deshaies | Proteasome pathway inhibitors and related methods |
| US7244757B2 (en) | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| MX2008010635A (es) | 2006-02-16 | 2008-10-28 | Schering Corp | Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares. |
| AR068046A1 (es) | 2007-06-05 | 2009-11-04 | Schering Corp | Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer |
| WO2008156739A1 (en) | 2007-06-18 | 2008-12-24 | Schering Corporation | Heterocyclic compounds and use thereof as erk inhibitors |
| DK2217597T3 (da) | 2007-10-01 | 2011-06-20 | Comentis Inc | Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom |
| WO2009105500A1 (en) | 2008-02-21 | 2009-08-27 | Schering Corporation | Compounds that are erk inhibitors |
| US8022227B2 (en) | 2008-08-27 | 2011-09-20 | The Ohio State University | Method of synthesizing 1H-indazole compounds |
| EP2408448A4 (en) | 2009-03-18 | 2012-09-19 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
| SI2455381T1 (sl) * | 2009-07-17 | 2014-08-29 | Japan Tobacco Inc. | Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina |
| JP2013506669A (ja) | 2009-09-30 | 2013-02-28 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｅｒｋ阻害剤である新規化合物 |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP3536319A1 (en) | 2010-10-29 | 2019-09-11 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| WO2012170845A2 (en) * | 2011-06-08 | 2012-12-13 | Heffernan Michele L R | Metabotropic glutamate receptor 5 modulators and methods of use thereof |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2014052566A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2014134772A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| US9745307B2 (en) | 2013-04-30 | 2017-08-29 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP3363800A1 (en) | 2013-10-03 | 2018-08-22 | Kura Oncology, Inc. | Heterocyclic inhibitors of erk and methods of use |
| WO2016095089A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| WO2016095088A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| CN107001322B (zh) | 2014-12-18 | 2020-07-28 | 默沙东公司 | 用于药物制剂的组合物 |
| MX2017008078A (es) | 2014-12-19 | 2017-09-28 | Merck Sharp & Dohme | Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas. |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
-
2014
- 2014-10-03 EP EP17204999.1A patent/EP3363800A1/en not_active Withdrawn
- 2014-10-03 KR KR1020167011270A patent/KR20160081908A/ko not_active Ceased
- 2014-10-03 MX MX2016004163A patent/MX2016004163A/es unknown
- 2014-10-03 SG SG11201602572YA patent/SG11201602572YA/en unknown
- 2014-10-03 EP EP14850964.9A patent/EP3052096B8/en active Active
- 2014-10-03 WO PCT/US2014/059197 patent/WO2015051341A1/en not_active Ceased
- 2014-10-03 CA CA2924584A patent/CA2924584A1/en not_active Abandoned
- 2014-10-03 RS RS20180373A patent/RS57058B1/sr unknown
- 2014-10-03 US US15/026,581 patent/US9624228B2/en not_active Expired - Fee Related
- 2014-10-03 ES ES14850964.9T patent/ES2664794T3/es active Active
- 2014-10-03 CN CN201480054909.3A patent/CN105636586B/zh not_active Expired - Fee Related
- 2014-10-03 HU HUE14850964A patent/HUE036600T2/hu unknown
- 2014-10-03 CN CN201810401122.XA patent/CN108864102A/zh active Pending
- 2014-10-03 EA EA201690708A patent/EA032196B1/ru not_active IP Right Cessation
- 2014-10-03 ME MEP-2018-90A patent/ME02991B/me unknown
- 2014-10-03 HR HRP20180538TT patent/HRP20180538T1/hr unknown
- 2014-10-03 PT PT148509649T patent/PT3052096T/pt unknown
- 2014-10-03 SM SM20180205T patent/SMT201800205T1/it unknown
- 2014-10-03 JP JP2016546894A patent/JP6427197B2/ja not_active Expired - Fee Related
- 2014-10-03 AU AU2014331628A patent/AU2014331628B2/en not_active Ceased
- 2014-10-03 BR BR112016006994A patent/BR112016006994A8/pt not_active Application Discontinuation
- 2014-10-03 SI SI201430659T patent/SI3052096T1/en unknown
- 2014-10-03 DK DK14850964.9T patent/DK3052096T3/en active
- 2014-10-03 PL PL14850964T patent/PL3052096T3/pl unknown
- 2014-10-03 LT LTEP14850964.9T patent/LT3052096T/lt unknown
-
2016
- 2016-03-07 PH PH12016500432A patent/PH12016500432A1/en unknown
- 2016-03-08 IL IL244488A patent/IL244488A0/en unknown
- 2016-03-11 ZA ZA2016/01701A patent/ZA201601701B/en unknown
-
2017
- 2017-02-22 US US15/439,719 patent/US9951078B2/en not_active Expired - Fee Related
-
2018
- 2018-02-14 US US15/896,929 patent/US10301317B2/en not_active Expired - Fee Related
- 2018-03-27 CY CY20181100340T patent/CY1120095T1/el unknown
- 2018-10-18 AU AU2018250439A patent/AU2018250439A1/en not_active Abandoned
- 2018-10-26 JP JP2018201905A patent/JP2019031549A/ja active Pending
- 2018-11-22 HK HK18114927.9A patent/HK1255851A1/en unknown
-
2019
- 2019-03-29 US US16/370,718 patent/US20190292194A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120095T1 (el) | Αναστολεις της erk και μεθοδοι χρησης | |
| CY1126855T1 (el) | Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου | |
| CY1120361T1 (el) | Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido) | |
| CY1124918T1 (el) | Ρυθμιστες ccr2 | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| EA201992497A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
| CY1124595T1 (el) | Ρυθμιση δραστικοτητας συμπληρωματος | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| EA202092000A1 (ru) | Ингибиторы димеризации egfr и их использование | |
| EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
| MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CY1118695T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
| CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CY1121550T1 (el) | Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης | |
| EA201890329A1 (ru) | СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ | |
| EA201591823A1 (ru) | Ингибиторы ido | |
| EA201991073A1 (ru) | Ингибиторы magl | |
| EA201991029A1 (ru) | Ингибиторы magl | |
| EA201690027A1 (ru) | Ингибиторы ido | |
| EA201690152A1 (ru) | Ингибиторы ido | |
| MX2019014041A (es) | Inhibidores pirazolicos de magl. | |
| CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος |